Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.43 |
| ▸ | KCNK2 | O95069 | 3/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 8/20 | 0.36 |
| ▸ | PTPRZ1 | P23471 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.33 |
| ▸ | FCER2 | P06734 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23460924 | 1.00 | CXCR2 (0.43) | CXCR2KCNK2PTPN2PTPN1PTPN7 | |
| SCHEMBL38666109 | 1.00 | CXCR2 (0.43) | CXCR2KCNK2PTPN2PTPN1PTPN7 | |
| SCHEMBL23461207 | 0.93 | CXCR2 (0.42) | CXCR2KCNK2PTPN2PTPN1PTPN7 | |
| SCHEMBL38664071 | 0.93 | CXCR2 (0.42) | CXCR2KCNK2PTPN2PTPN1PTPN7 | |
| SCHEMBL23461209 | 0.93 | CXCR2 (0.42) | CXCR2KCNK2PTPN2PTPN1PTPN7 | |
| SCHEMBL38147099 | 0.93 | CXCR2 (0.41) | CXCR2KCNK2PTPN2PTPN1PTPN7 | |
| SCHEMBL23461433 | 0.93 | CXCR2 (0.41) | CXCR2KCNK2PTPN2PTPN1PTPN7 | |
| SCHEMBL23461434 | 0.93 | CXCR2 (0.41) | CXCR2KCNK2PTPN2PTPN1PTPN7 | |
| SCHEMBL25549232 | 0.91 | CXCR2 (0.41) | CXCR2KCNK2PTPN2PTPN1PTPN7 | |
| SCHEMBL23461505 | 0.91 | CXCR2 (0.43) | CXCR2KCNK2PTPN2PTPN1PTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2021113806-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885KCNK2 1269/4885PTPN2 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.